US008853156B2

(12) **United States Patent**
Dugi et al.

(10) **Patent No.: US 8,853,156 B2**
(45) **Date of Patent: Oct. 7, 2014**

(54) **TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY**

(75) Inventors: **Klaus Dugi**, Dresden (DE); **Eva Ulrike Graefe-Mody**, Biberach (DE); **Ruth Harper**, Reading (GB); **Hans-Juergen Woerle**, Munich (DE)

(73) Assignee: **Boehringer Ingelheim International GmbH**, Ingelheim am Rhein (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 577 days.

(21) Appl. No.: **13/057,295**

(22) PCT Filed: **Aug. 5, 2009**

(86) PCT No.: **PCT/EP2009/060170**
§ 371 (c)(1),
(2), (4) Date: **Apr. 15, 2011**

(87) PCT Pub. No.: **WO2010/015664**
PCT Pub. Date: **Feb. 11, 2010**

(65) **Prior Publication Data**

US 2011/0263493 A1 Oct. 27, 2011

Related U.S. Application Data

(60) Provisional application No. 61/086,620, filed on Aug. 6, 2008, provisional application No. 61/105,915, filed on Oct. 16, 2008.

(30) **Foreign Application Priority Data**

Aug. 7, 2008 (EP) 08161989
Oct. 16, 2008 (EP) 08166827

(51) **Int. Cl.**

A61K 38/00	(2006.01)
A61K 38/28	(2006.01)
A61P 3/10	(2006.01)
A61P 7/12	(2006.01)
C07K 14/62	(2006.01)
A01N 43/58	(2006.01)
A01N 43/60	(2006.01)
A61K 31/50	(2006.01)
A61K 31/495	(2006.01)
A61K 31/52	(2006.01)
A61K 31/513	(2006.01)
A61K 31/4375	(2006.01)
A61K 31/4439	(2006.01)
A61K 31/427	(2006.01)
A61K 31/422	(2006.01)
A61K 31/403	(2006.01)
A61K 31/4025	(2006.01)
A61K 31/40	(2006.01)
A61K 31/506	(2006.01)
A61K 31/4985	(2006.01)
A61K 31/522	(2006.01)
A61K 31/5025	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/40*** (2013.01); ***A61K 31/513*** (2013.01); ***A61K 31/4375*** (2013.01); ***A61K 31/4439*** (2013.01); ***A61K 31/427*** (2013.01); ***A61K 31/422*** (2013.01); ***A61K 31/403*** (2013.01); ***A61K 31/4025*** (2013.01); ***A61K 31/506*** (2013.01); ***A61K 31/4985*** (2013.01); ***A61K 31/522*** (2013.01); ***A61K 31/5025*** (2013.01)
USPC **514/6.9**; 514/5.9; 514/248; 514/263.2; 514/263.21; 514/263.22

(58) **Field of Classification Search**
CPC combination set(s) only.
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,056,046	A	9/1936	Fourneau
2,375,138	A	5/1945	Salvin
2,629,736	A	2/1953	Krimmel
2,730,544	A	1/1956	Sahyun
2,750,387	A	6/1956	Krimmel
2,928,833	A	3/1960	Leake et al.
3,174,901	A	3/1965	Sterne
3,236,891	A	2/1966	Seemuller
3,454,635	A	7/1969	Muth
3,673,241	A	6/1972	Marxer
3,925,357	A	12/1975	Okada et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU	2003280680	A1	6/2004
AU	2009224546	A1	9/2009
CA	1123437	A1	5/1982
CA	2136288	A1	5/1995
CA	2418656	A1	2/2002
CA	2496249	A1	3/2004
CA	2496325	A1	3/2004

(Continued)

OTHER PUBLICATIONS

Kanada, S. et al., "Safety, tolerability, pharmacokenetics and pharmacodynamics of multiple doses of BI 1356 (proposed tradename Ondero), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes" Diabetes, vol. 57, No. Suppl. 1, Jun. 2008, p. A158-A159 and 68th Annual Meeting of the American Diabetes Association: San Francisco, CA, Jun. 6-10, 2008.

(Continued)

Primary Examiner — Marcela M Cordero Garcia
(74) *Attorney, Agent, or Firm* — Michael P. Morris; David L. Kershner

(57) **ABSTRACT**

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.

25 Claims, No Drawings